Skip to main content
OpenTrials
Completed

NCT Number: NCT00897234

Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with non-small cell lung cancer and from healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Masonic Cancer Center at University of Minnesota

Minneapolis, Minnesota, 55455, United States

About this study

OBJECTIVES:

  • Measure plasma cathepsin D levels in patients with non-small cell lung cancer and in healthy volunteers using mass spectometry.
  • Measure fatty acid synthase levels in these patients and healthy volunteers using mass spectometry.

OUTLINE: Blood samples are collected from patients and healthy volunteers to measure the levels of cathepsin D and fatty acid synthase by proteomic profiling and mass spectrometry.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Non-Small Cell Lung Cancer Patients

  • Documented diagnosis of non-small cell lung cancer, any stage and any time point in the course of treatment (i.e., at diagnosis, during any treatment, and during post treatment surveillance)
  • Measurable disease by CT scan within the past 4 weeks

Healthy volunteer

  • Non-smoking, defined as < 5 packs/year history of smoking and cessation of smoking ≥ 6 months ago OR a never smoker
  • Not regularly exposed (i.e., daily) to second-hand smoke

Exclusion criteria

  • Severe underlying lung disease (i.e., chronic obstructive pulmonary disease with FEV_1 < 1.0 L, pulmonary fibrosis, bronchiectasis, cystic fibrosis, etc.) as determined by enrolling researcher.

Written consent must be given for both subjects and controls.

Treatment and study plan

mass spectrometry

Other

Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.

Primary outcomes

  1. Levels of cathepsin D

    Time frame: At Routine Follow-Up

    Measure plasma CD levels in patients with non-small cell lung cancer and non-smoker healthy controls using mass spectrometry.

Secondary outcomes

  1. Levels of fatty acid synthase (FAS)

    Time frame: At Routine Follow-Up

    Measure FAS levels in patients with non-small cell lung cancer and non-smoker healthy controls using mass spectrometry.

  2. Global microRNA expression

    Time frame: At Routine Follow-Up

    Measure global microRNA expression by microarray analysis using Illumina probes.

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

Plasma Quantification of Cathepsin D and FAS in Non-Small Cell Lung Cancer

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
May 12, 2009
Registry last updated
Aug 22, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.